Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
US Stock MarketDetailed Quotes
SPRY ARS Pharmaceuticals
- 14.439
- +0.059+0.41%
Trading Apr 24 15:22 ET
1.42BMarket Cap180.49P/E (TTM)
14.730High14.200Low414.65KVolume14.460Open14.380Pre Close5.98MTurnover0.89%Turnover Ratio180.49P/E (Static)98.12MShares18.51052wk High5.52P/B671.71MFloat Cap7.55052wk Low--Dividend TTM46.52MShs Float63.410Historical High--Div YieldTTM3.69%Amplitude2.550Historical Low14.428Avg Price1Lot Size
ARS Pharmaceuticals Stock Forum
Sign in to post a comment
$ARS Pharmaceuticals (SPRY.US)$
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is a biopharmaceutical company focused on developing and commercializing neffy, a needle-free intranasal epinephrine spray designed for emergency treatment of Type I allergic reactions, including anaphylaxis. Below is an analysis of SPRY stock based on available data as of March 17, 2025:
### Company Overview
- Product: Neffy is the first FDA-approved needle-free epinephrine delivery system, offering an al...
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is a biopharmaceutical company focused on developing and commercializing neffy, a needle-free intranasal epinephrine spray designed for emergency treatment of Type I allergic reactions, including anaphylaxis. Below is an analysis of SPRY stock based on available data as of March 17, 2025:
### Company Overview
- Product: Neffy is the first FDA-approved needle-free epinephrine delivery system, offering an al...
6
1
1
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If y...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If y...
34
7
$ARS Pharmaceuticals (SPRY.US)$ Reuters
just
ARS Pharmaceuticals Announces FDA Approval of Neffy® 1 Mg (Epinephrine Nasal Spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to
just
ARS Pharmaceuticals Announces FDA Approval of Neffy® 1 Mg (Epinephrine Nasal Spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to
5
$ARS Pharmaceuticals (SPRY.US)$
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
Positive
First FDA-approved needle-free epinephrine nasal spray
Rapid inclusion on Express Scripts Commercial National Formularies (9 weeks post-launch)
Access to millions of commercially insured patients
Superior product features: 30-month shelf-life, high temperature tolerance (122°F)
Negative
to patients weighing ≥30 kg (66 lbs.)
Current...
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
Positive
First FDA-approved needle-free epinephrine nasal spray
Rapid inclusion on Express Scripts Commercial National Formularies (9 weeks post-launch)
Access to millions of commercially insured patients
Superior product features: 30-month shelf-life, high temperature tolerance (122°F)
Negative
to patients weighing ≥30 kg (66 lbs.)
Current...
1
$ARS Pharmaceuticals (SPRY.US)$
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
Agreement leverages ALK's global footprint in developing and commercializing innovative allergy products
ARS Pharma to receive an upfront cash payment of $145 million, with total deal consideration of up to $465 million plus double-digit royalties on net sales
ARS Pharma retains all U.S. rig...
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
Agreement leverages ALK's global footprint in developing and commercializing innovative allergy products
ARS Pharma to receive an upfront cash payment of $145 million, with total deal consideration of up to $465 million plus double-digit royalties on net sales
ARS Pharma retains all U.S. rig...
3
2
$ARS Pharmaceuticals (SPRY.US)$ Showcases Intranasal Epinephrine Data At 2024 American College Of Allergy, Asthma & Immunology Annual Scientific Meeting, Friday October 25.
No comment yet
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
mohd ammi bin ismail : hello